Janssen Pharmaceutica N.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has signed a sponsored research agreement with the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University.
The agreement has been signed between both of them to advance the development of an inhaled version of oxytocin in order to help prevent and manage Post-Partum Hemorrhage (PPH).
Jaak Peeters, Global Head, Johnson & Johnson Global Public Health, Janssen-Cilag GmBH, said, “When you consider the lifetime risk of dying for a woman in childbirth is 23 times higher in resource-limited settings than anywhere else you must act if you have the scientific capabilities to potentially help overcome that inequity. We hope to address this significant unmet need by helping accelerate the development of what would be a truly life-saving innovation and give women and their families everywhere the same chance at life.”
Michelle McIntosh, Monash Institute of Pharmaceutical Sciences, Monash University, added, “This is an exciting opportunity to expand this collaboration between industry and academia to develop an important healthcare innovation that aims to address a critical unmet medical need. There is a massive ripple effect when a mother dies – it's a very significant burden for these families and communities, and we are committed to bringing the gold-standard care to all mothers.”
Kathy Connell, Senior Director, New Ventures, Australia & New Zealand, Johnson & Johnson Innovation, further stated, “This latest agreement between Johnson & Johnson and Monash University, an internationally renowned leader in pharmacy and pharmacology, builds on our legacy of innovative academic-industry collaborations in Australia focused on developing life-saving treatments for the highest unmet needs.”
